Seres Therapeutics

Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Seres Therapeutics poised for FDA approval with strong pipeline progress

Seres Therapeutics is well-positioned for potential FDA approval of SER-109, backed by strong Phase III efficacy and safety data. The company's financial stability and strategic collaborations underscore a focused approach towards commercial success. Addressing key challenges and leveraging opportunities in product development and market entry will be crucial for Seres Therapeutics' future growth.

Seres Therapeutics secures FDA approval for VOWST, eyes commercial success

Seres Therapeutics is poised for success with FDA approval of VOWST and positive study results for SER-155. The company faces challenges in ensuring consistent engraftment and optimizing operational efficiencies. Opportunities lie in commercializing VOWST and advancing microbiome therapeutics.

Seres Therapeutics reports robust Q2 earnings, eyes VOWST growth

Seres Therapeutics had a strong Q2 2023, propelled by VOWST approval and positive sales performance, positioning the company for continued growth.
While facing challenges like Medicare affordability issues and net losses, Seres remains optimistic about VOWST's potential and profitability trajectory.
By capitalizing on opportunities in education, expansion, and efficiency, Seres aims to drive VOWST adoption, enhance market presence, and achieve financial success.

Seres Therapeutics excels in Q3 with VOWST launch success

Seres Therapeutics reported a strong Q3 performance with the successful VOWST launch, despite a net loss. The company's restructuring focuses on VOWST's growth and long-term sustainability. Challenges include optimizing VOWST sales and navigating reimbursement differences.

Seres Therapeutics excels in 2023 with VOWST launch and financial focus

Seres Therapeutics had a strong 2023, marked by successful product launches, financial discipline, and promising development in microbiome therapeutics.
The company's strengths include innovation, financial stability, strong leadership, and efficient budget management, positioning them for future growth.
Challenges include sustaining momentum, securing funding for advancement, meeting regulatory expectations, and ensuring positive patient experiences.
Opportunities lie in continued growth, partnerships, strategic funding, innovation, and establishing a compelling market narrative.
Overall, Seres Therapeutics is well-positioned for success in the microbiome therapeutics market, with a focus on product development and financial discipline.

Seres Therapeutics reports robust Q1 sales and advances pipeline growth

Seres Therapeutics demonstrated strong sales performance with VOWST net sales reaching $10.1 million in Q1 2024.
The company's focus on commercialization of VOWST and advancement of microbiome therapeutic candidates like SER-155 shows promise for future growth.
Challenges in pricing, inventory management, and funding are being addressed, while opportunities in new patient populations and strategic partnerships are being explored.

Seres Therapeutics sells VOWST assets, reports strong Q2 earnings

Seres Therapeutics' Q2 performance was marked by a strategic asset sale, strong financial results, and progress in key pipeline programs. The company's focus on transformative therapies and data-driven pipeline prioritization positions it well for future growth and impact in the healthcare sector.

Seres Therapeutics reports Q3 loss but sees growth opportunities ahead

Seres Therapeutics faced a net loss in Q3 2024 but maintained strong cash reserves for operations into Q4 2025.
Positive results from SER-155 and the VOWST sale present opportunities for growth and addressing bacterial infections in patients.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The company's new dug could be a game changer.

Why Seres Therapeutics Stock Skyrocketed 350% Today

Shares of the small-cap biopharma Seres Therapeutics Inc (NASDAQ: MCRB) were ripping higher Monday.

Seres Therapeutics Skyrockets On Positive Pivotal Study Results For Microbiome Therapeutic

Seres Therapeutics Inc. (NASDAQ: MCRB) shares more than tripled early on Monday after the firm announced positive late-stage results for its C.

Good News for C Diff Sufferers and Seres Therapeutics Investors

Shares of Seres Therapeutics Inc. MCRB, +4.74% rocketed nearly fourfold (up 270%) on heavy volume in premarket trading Monday, after the microbiome therapeutics company reported upbeat results of a Phase 3 trial of its SER-109 for recurrent C.

Seres Therapeutics stock rockets nearly fourfold after positive Phase 3 data on treatment for colon infections

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $MCRB--SER-109 met Phase 3 primary endpoint, showing highly statistically significant 30.2% absolute reduction in the rate of C.

Seres Therapeutics Announces Positive Topline Results from SER-109 Phase 3 ECOSPOR III Study in Recurrent C. difficile Infection

Investors need to pay close attention to Seres Therapeutics (MCRB) stock based on the movements in the options market lately.

Do Options Traders Know Something About Seres Therapeutics (MCRB) Stock We Don't?

Seres Therapeutics (MCRB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Seres Therapeutics (MCRB) Q2 Earnings Expected to Decline

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $MCRB--Topline data from SER-109 Phase 3 study in recurrent C.

Seres Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Updates

Seres Therapeutics (MCRB) saw a big move last session, as its shares jumped nearly 11% on the day, amid huge volumes.

Seres Therapeutics (MCRB) in Focus: Stock Moves 10.8% Higher

Seres Therapeutics, Inc. (MCRB) CEO Eric Shaff on Q1 2020 Results - Earnings Call Transcript

Seres Therapeutics: Clinical Data Coming Soon

Seres Therapeutics, Inc. (MCRB) CEO Eric Shaff on Q4 2019 Results - Earnings Call Transcript

Seres Therapeutics, Inc. (MCRB) CEO Eric Shaff on Q3 2019 Results - Earnings Call Transcript

Seres Therapeutics (MCRB) delivered earnings and revenue surprises of 11.54% and 5.16%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Seres Therapeutics (MCRB) Reports Q3 Loss, Tops Revenue Estimates

As of late, it has definitely been a great time to be an investor in Seres Therapeutics, Inc. (MCRB).

Seres Therapeutics, Inc. (MCRB) Shares March Higher, Can It Continue?

Seres Therapeutics, Inc. (MCRB) CEO Eric Shaff on Q2 2019 Results - Earnings Call Transcript

Seres Therapeutics (MCRB) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Anaplan Inc

Athenex

Chubb

Chewy

MGM Resorts

Smartsheet

The GuruFocus All-in-One Screener can be used to find insider trades from the past week.

Largest insider trades of the week: June 21

Seres Therapeutics (MCRB) CEO Eric Shaff on Q1 2019 Results - Earnings Call Transcript

Axovant Gene Therapies Ltd

Lonestar Resources US

Tellurian

Zynga

Most firms on Wall Street focus on large and mega cap stocks, as they provide a degree of safety and liquidity.

5 New Stocks Trading Under $10 With Monumental Implied Upside

Seres Therapeutics (MCRB) delivered earnings and revenue surprises of -27.91% and -15.00%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Seres Therapeutics (MCRB) Reports Q1 Loss, Lags Revenue Estimates

A new collaboration with AstraZeneca could give microbiome-based medicine a big lift.

Here's Why Seres Therapeutics Stock Soared Today

Chaparral Energy Inc - Ordinary Shares - Class A

Caesars Entertainment

Noodles & Co.

Aurora Cannabis

While most of Wall Street focuses on large and mega cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

News for Seres Therapeutics Stock (MCRB)